Skip to content
Intent.Health — AI That’s Natively Healthcare

Intent.Health Supplier Deep View: How Healthcare Suppliers Move Innovation to Care

The Healthcare Value Chain

How innovation physically and financially moves to the patient.

1. Manufacturer

Pharma, MedTech, Biotech

  • R&D & Clinical Trials
  • Regulatory Approval (FDA)
  • Market Access Strategy

2. Intermediary

Wholesalers, GPOs, PBMs

  • Contract Negotiation (GPO)
  • Logistics & Distribution
  • Formulary Management (PBM)

3. Provider

Hospitals, Clinics, Pharmacies

  • Procurement & Inventory
  • Prescribing & Usage
  • Patient Administration

4. End User

Patients & Payers

  • Consumption / Outcomes
  • Reimbursement
  • Copay & Deductibles

Intent Insight: You cannot sell directly to a hospital without navigating the Intermediary Layer (GPOs for MedTech, Wholesalers for Pharma).

Market Segments

The Supplier Micro-Ecosystems

High Margin

Pharmaceuticals

Driven by R&D cliffs and patent life. Distribution flows through the "Big 3" wholesalers (McKesson, Cardinal, AmerisourceBergen). Sales target Prescribers, but access is controlled by PBM Formularies.

Key Players:

Pfizer, Merck, J&J, AbbVie

High Competition

Medical Devices

Ranges from consumables (gloves) to capital (MRI). Heavy reliance on GPO contracts for access. Sales involve Value Analysis Committees (VAC) and clinical champions.

Key Players:

Medtronic, Stryker, GE HealthCare

Rapid Growth

Healthcare IT

EHRs, RCM, and Telehealth. The challenge is interoperability and workflow integration. Sales target the CIO and CMIO. Security (HIPAA) is the primary blocker.

Key Players:

Epic, Oracle Health, Change Healthcare

Consumer Facing

The Retail View

Pharmacies, DME (Durable Medical Equipment), and Home Health supplies. Moving towards direct-to-consumer and "health hub" models.

Key Players:

CVS, Walgreens, Apria, Amazon

The "Valley of Death"

The rigorous path from idea to market access.

Funding & R&D

Angel & VC Capital: Funding high-risk innovation. Most startups fail here.
Key Insight: Investment must be aligned with a clear exit strategy (acquisition by a major supplier).

Regulatory Clearance (FDA)

The Gatekeeper: Determining safety and efficacy.
Pathways: 510(k) (Substantial Equivalence) vs. PMA (Pre-Market Approval: Rigorous).

Reimbursement Coding

Getting Paid: Even if approved, if there is no CPT/DRG code, providers won't buy it. You must secure coverage from CMS and Private Payers.

Market Access & Sales

The Final Mile: Getting on GPO contracts, passing VAC reviews, and driving utilization with clinicians.

YOUR NEXT MOVE

Bring your market into focus.

See how organizations, people, clinical activity and intent come together for your team.

Explore your use case ↗